OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
Noritoshi Kobayashi, Yuma Takeda, Naoki Okubo, et al.
Cancer Science (2021) Vol. 112, Iss. 5, pp. 1936-1942
Open Access | Times Cited: 15
Noritoshi Kobayashi, Yuma Takeda, Naoki Okubo, et al.
Cancer Science (2021) Vol. 112, Iss. 5, pp. 1936-1942
Open Access | Times Cited: 15
Showing 15 citing articles:
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Xiaoying Hou, Hongzhi Du, Yufei Deng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 31
Xiaoying Hou, Hongzhi Du, Yufei Deng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 31
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
European Journal of Cancer (2024) Vol. 208, pp. 114129-114129
Open Access | Times Cited: 4
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
European Journal of Cancer (2024) Vol. 208, pp. 114129-114129
Open Access | Times Cited: 4
Rare epithelial gastric cancers: a review of the current treatment knowledge
Angelica Petrillo, Margaret Ottaviano, Luca Pompella, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Angelica Petrillo, Margaret Ottaviano, Luca Pompella, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis
Erfan Taherifard, Muhammad Bakhtiar, Mahnoor Mahnoor, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Erfan Taherifard, Muhammad Bakhtiar, Mahnoor Mahnoor, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Chemotherapy in NEN: still has a role?
Paula Espinosa-Olarte, Anna La Salvia, María Carmen Riesco Martínez, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 3, pp. 595-614
Open Access | Times Cited: 19
Paula Espinosa-Olarte, Anna La Salvia, María Carmen Riesco Martínez, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 3, pp. 595-614
Open Access | Times Cited: 19
Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives
Francesca Corti, Roberta Rossi, Pietro Cafaro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2025-2025
Open Access | Times Cited: 2
Francesca Corti, Roberta Rossi, Pietro Cafaro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2025-2025
Open Access | Times Cited: 2
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
M. Robinson, Daniel Livesey, Richard Hubner, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 6
M. Robinson, Daniel Livesey, Richard Hubner, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 6
Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon
Anna La Salvia, Irene Persano, Elena Parlagreco, et al.
Medical Oncology (2022) Vol. 39, Iss. 11
Closed Access | Times Cited: 6
Anna La Salvia, Irene Persano, Elena Parlagreco, et al.
Medical Oncology (2022) Vol. 39, Iss. 11
Closed Access | Times Cited: 6
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
Jamie Weaver, Richard Hubner, Juan W. Valle, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 4951-4951
Open Access | Times Cited: 3
Jamie Weaver, Richard Hubner, Juan W. Valle, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 4951-4951
Open Access | Times Cited: 3
Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives
Elettra Merola, Andrea Michielan, Umberto Rozzanigo, et al.
World Journal of Gastrointestinal Surgery (2022) Vol. 14, Iss. 2, pp. 78-106
Open Access | Times Cited: 1
Elettra Merola, Andrea Michielan, Umberto Rozzanigo, et al.
World Journal of Gastrointestinal Surgery (2022) Vol. 14, Iss. 2, pp. 78-106
Open Access | Times Cited: 1
Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
Daisuke Sato, Hirokazu Takami, Takayanagi Shunsaku, et al.
Research Square (Research Square) (2023)
Open Access
Daisuke Sato, Hirokazu Takami, Takayanagi Shunsaku, et al.
Research Square (Research Square) (2023)
Open Access
Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
Nikolaos Andreatos, Patrick W. McGarrah, Mohamad Bassam Sonbol, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 10, pp. 1127-1139
Closed Access
Nikolaos Andreatos, Patrick W. McGarrah, Mohamad Bassam Sonbol, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 10, pp. 1127-1139
Closed Access
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Maria A. Velez, Edward B. Garon
Clinical Cancer Research (2022) Vol. 29, Iss. 4, pp. 691-693
Closed Access
Maria A. Velez, Edward B. Garon
Clinical Cancer Research (2022) Vol. 29, Iss. 4, pp. 691-693
Closed Access
